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Background: The preclinical stage of systolic heart failure (HF), known as
asymptomatic left ventricular dysfunction (ALVD), is diagnosed only by
echocardiography, frequent in the general population and leads to a high risk
of developing severe HF. Large scale screening for ALVD is a difficult task
and represents a major unmet clinical challenge that requires the determination
of ALVD biomarkers.
Methodology/Principal Findings: 294 individuals were screened by
echocardiography. We identified 9 ALVD cases out of 128 subjects with car-
diovascular risk factors. White blood cell gene expression profiling was per-
formed using pangenomic microarrays. Data were analyzed using principal
component analysis (PCA) and Significant Analysis of Microarrays (SAM).
To build an ALVD classifier model, we used the nearest centroid classifica-
tion method (NCCM) with the ClaNC software package. Classification perfor-
mance was determined using the leave-one-out cross-validation method.
Blood transcriptome analysis provided a specific molecular signature for
ALVD which defined a model based on 7 genes capable of discriminating
ALVD cases. Analysis of an ALVD patients validation group demonstrated
that these genes are accurate diagnostic predictors for ALVD with 87% accu-
racy and 100% precision. Furthermore, Receiver Operating Characteristic
curves of expression levels confirmed that 6 out of 7 genes discriminate for
left ventricular dysfunction classification.
Conclusions/Significance: These targets could serve to enhance the ability
to efficiently detect ALVD by general care practitioners to facilitate preemp-
tive initiation of medical treatment preventing the development of HF.
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Background. Acute heart failure may induce increased level of plasmatic
troponin. The aim of this study was to assess the diagnostic and prognostic
value of troponin I in acute cardiogenic pulmonary edema.
Methods. We studied 619 consecutive patients admitted to our institution
for acute cardiogenic pulmonary edema during a six years period (from Jan-
uary 2003 to December 2009). Baseline characteristics, ECG, biological
markers (including troponin I) and in-hospital mortality were systematically
analyzed. Patients with increased troponin underwent coronary angiography.
Results. Prevalence of increased plasmatic troponin level was 48%
(n=297) of acute pulmonary edema. Diabetes (p=0.01), ECG signs of myocar-
dial ischemia (p<0.0001) and chest pain (p<0.0001) were more frequently
found in patients with increased levels of troponin. Among these patients, a
coronary artery disease was only diagnosed in 166 patients (56%), but was
more frequently diagnosed in patients with chest pain (72%, p=0.01) and in
patients with previous history of CAD (81%, p<0.01). The duration of hospi-
talization and the in-hospital mortality rate were significantly higher in
patients with increased plasmatic troponin level (mortality: 8.4% versus 3.1%;
p<0.004). In multivariate analysis, increased plasmatic troponin level was
independently related to death (OR=2.3, 95% CI: 1.3-20.1, p=0.02).
Background. Increased plasmatic troponin level is found in 48% of
patients presenting with acute pulmonary edema, but is related to coronary
artery disease in only 56%. Interestingly, increased plasmatic troponin level is
related to an independent increased risk of mortality in patients with acute pul-
monary edema.
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Aims: Systolic blood pressure (SBP) level is positively correlated with sur-
vival in chronic systolic heart failure (CHF) and negatively with arterial
hypertension disease. A high level of blood pressure variability (BPV) repre-
sents, especially in arterial hypertension disease, a stronger cardiovascular
risk. The aim of our study was to evaluate the pronostic impact of BPV level
by ambulatory monitoring blood pressure (AMBP) in CHF.
Methods: We retrospectively collected AMBP of 288 patients (60±12
years, males 227(79%)) hospitalized for CHF (47% NYHA III&IV, LVEF
28±9%) between 1999 and 2006. After retrieving characteristics, such as dia-
betes (21%), Hypertension (43%) or etiology (ischemic 45%), follow up was
realized retrospectively using physician, patient or family phone contact
during 2010. The composite outcome was defined by all causes of death and/
or heart transplant. Logrank mantel cox (qualitative), cox model (quantitative)
and cox stepwise logistic regression were used to perform univariate (table 2)
and multivariate analysis factors on outcome.
Results: During a mean follow up of 7 years, the composite outcome was
observed for 71 (32.2 %) patients (6 heart transplants and 65 deaths). High
SBP (mean 110±15), DBP (68±10), systolic BPV daytime (23±9) levels are
positively correlated with survival in univariate analysis. Multivariate analysis
included age, diabetes, BMI, NYHA, systolic BPV daytime, (SBP daytime
and nighttime), DBP (daytime, nightime), Pulse pressure (daytime nighttime)
and worse congestive state at the admission. Thus, NYHA class III/IV
(RR=5.1, p<0.01) and systolic BPV daytime (RR=0.963, p<0.03) were found
to be the two independent factors of survival. Arbitrary poor pronostic value
cut off at <19 mmHg was chosen to represent impact of systolic BPV daytime
on cumulative outcome (RR=1.65, 95 % IC 1-2.7; p<0.04).
Conclusion: In this population of 288 patients with CHF, a high level of
BPV daytime is an independent factor of survival.
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Objective: To determine whether sleep-disordered breathing (SDB)
severity, pattern, polygraphic variables and their ventilatory treatment in
chronic heart failure (CHF) were associated with adverse CHF outcomes.
Background: SDB are frequent in CHF. The relationships bewteen SDB
and outcome in CHF are unknow.
Methods: 384 CHF patients with LVEF <45% were assessed by a polyg-
raphy in our CHF clinic. Ventilatory treatment was started according to SDB
severity. Combined endpoint was death, heart tranplant and ventricular assit
device implant.
Results: Of the 384 CHF, their mean (SD) age was 59+/–13, LVEF was
299 and 82%% were men. Obstructive sleep apnoea (OSA), central sleep
apnoea (CSA) and Cheyne-Stockes respiration (CSR) prevalences were 62%,
26% and 29%. Primary endpoint was observed in 31%. Mean (SD) follow-up
for survivors was 47+/– 25months. Moderate (5.h-120.h-1), OSA and CSA
had a similar bad prognostic compared to patients without SDB (respectively
p=0.036; p=0.003). 31% of the SDB patients received a ventilatory treatment
of whom 98% had severe SDB. Treated SDB had a better outcome than
untreated severe SDB after adjustement for cofounding factors (p=0.031; HR:
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0.56; 95%CI [0.33-0.95]). Subgroup analysis including only OSA showed a
similar result after adjustement (p=0.017; HR: 0.40; 95%CI [0.19-0.95]). In
multivariate cox analysis including all the polygraphic variables, only CSR
and minimal oxyhemoglobin saturation predicted adverse outcomes in all CHF
patients untreated for SDB but AHI.
Conclusion: In patients with CHF, ventilatory treatment of SDB is associ-
ated with a better outcome independently of confounding factors.
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Background: Acute decompensated heart failure is a challenging diagnosis
when natriuretic peptides are misleading. Midregional-proadrenomedullin
(MR-proADM) is a new prognostic peptide in heart failure.
Objectives: This preliminary study sought to assess the diagnostic accu-
racy of MR-proADM in heart failure in comparison with B-type natriuretic
peptide (BNP) according to the echocardiographic estimation of left ventric-
ular filling pressures (LVFP). The second purpose was to establish a cut-off
value of MR-proADM between stable and decompensated heart failure.
Methods: We measured BNP and MR-proADM plasma levels in 35 con-
secutive patients. Concomitantly, we performed a doppler echocardiography,
measuring the ratio of mitral velocity to early diastolic velocity of the mitral
annulus (E/e'). 25 patients were suspected of congestive heart failure and 10
patients were suffering from stable heart failure.
Results: Ischemic and dilated cardiomyopathies were the two major causes
of heart failure in our population (43% vs 31%), with only 17% of heart
failure with preserved ejection fraction. Median MR-proADM and BNP levels
were 0,94 nmol/L and 552 pg/mL respectively. Both plasma levels were
scaling up with the NYHA classification. The correlation between the E/e’
ratio and BNP levels was better than between E/e' and MR-proADM levels
(r=0,63 vs 0,41 respectively). A mild correlation was found between BNP and
MR-proADM, probably due to their shared prognostic value. MR-proADM
could classify most of the patients with intermediate BNP levels according to
the echocardiographic estimation of LVFP.
Conclusions: This preliminary study shows that MR-proADM may be of
interest for the diagnosis of decompensated heart failure in patients with inter-
mediate BNP levels. MR-proADM levels > 0,74 nmol/L would correlate with
the elevation of LVFP as determined by the E/e’ ratio, and thus be useful
when echocardiography is not available.
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CHU Bordeaux, Bordeaux, France
Background: Patients suffering from heart failure (HF) have constant
exaggerated hyperventilation (high VE/VCO2) leading to breathlessness and
reduced exercise capacity. Metaboreflex over activation has been proposed to
partly explain this high ventilatory response during exercise.
Objective: We aim to investigate the modification of the metaboreflex
activation as a determinant in the improvement of the ventilatory response
6 months after CRT.
Methods and results: 10 HF patients (mean left ventricular ejection (LVEF)
27±4%, peak VO2 14±4 ml/kg/min, NYHA class 2,6±0,5; QRS duration
>120 ms) schedulded for CRT implantation were prospectively studied. At base-
line and after 6 month follow up two maximal cardiopulmonary exercise tests with
and without regional circulatory occlusion (RCO) were performed with contin-
uous VE, respiratory ratio (RR), VCO2 and VO2 measurements. RCO was
achieved by inflation of bilateral upper thigh tourniquets 30 mmHg above peak
systolic blood pressure during 3 minutes after peak exercise as previously
described. Metaboreflex contribution to the ventilatory response was assessed as
the difference in ventilatory data at the third minute during recovery between the
two tests (RCO – no RCO=). At baseline, patients had enhanced VE/VCO2
slope (40±9) and an evident metaboreflex contribution to the high ventilatory
response (VE: 3±4 L/min; p=0.01, RR: 4.5±4/min; p=0.01). 6 months after
CRT implantation, NYHA class, LVEF, peak VO2 and VE/VCO2 were signifi-
cantly improved (1,5±0,5; p<0.001, 42±7%; p<0.001, 16±4 ml/kg/min; p=0.005;
33±9; p=0.001). Metaboreflex contribution to ventilation was reduced compared
with baseline (VE: –1±5; p=0.08, RR: –1±3; p=0.01).
Conclusion: 6 months after CRT metaboreflex contribution to ventilation
is reduced and appears as an explanation in the ventilatory response improve-
ment in HF population.
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Colette Rio [Orateur], Pierre Nazeyrollas, Angeline Martin, Raphael San-
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Pierre Chabert, Damien Metz
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Introduction: it remains controversial whether pacemaker lead implanta-
tions could interfere with tricuspid valve function. The use of rigid and thicker
ventricular leads with implantable cardioverter-defibrillators (ICD) may
increase this risk. We realised a prospective study to analyse the tricuspid
valve function in this setting.
Method: we included patients needing a first ICD between october 2009
and may 2010 and performed echocardiographic recordings the day before
implantation, during the 3 following days and at 6 weeks. These records were
analysed offline independently by 2 cardiologists to assess and grade tricuspid
valve regurgitation (TR) using PISA and semi-quantitative method, and to
measure ventricular dimensions, function and pressures.
Results: we included 32 patients, 29 males, aged 61±14. Hypokinetic car-
diopathy accounted for 26 and 24 were implanted for primary prevention.
Ejection fraction was 35±14 %. Non significant TR was found in 23 patients
and only 2 patients has a tricuspid regurgitation greater than mild. The only
significant changes occurring immediately after defibrillator implantation con-
cerned TR, with a mean volume raising from 3.1±3.2 ml to 6.1±7.0 ml
(p<0.01) and a ROS from 0.03±0.3 to 0.06±0.07 cm² (p<0.01). Six TR
changed from not significant to minime (3) or mild (3), 3 from minime to
mild. Two patients with a baseline mild TR raised the regurgitant volume
from 11 ml to 19 ml and 30 ml. Mean regurgitant fraction increased from
5.5% to 10.5% and was higher in patients with a low ejection fraction and
mild TR at baseline. At 6 weeks, the results were similar. From a clinical
standpoint, no death occurred, and no worsening of heart failure was noticed.
Conclusion: we found a significant but minor increase in TR after defibril-
lator implantation, with no foreseeable consequences. However, our data hint
that this increase may be relevant in patients with the greater baseline regur-
gitation and the lower cardiac output
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Purpose: Cardiovascular disease patterns are changing in Africa. We
aimed to document the current heart failure (HF) patterns in Djibouti.
Methods: We prospectively included Djiboutian adults hospitalized for HF
in the French Military Hospital (Djibouti) between August 2008 and
December 2010. Clinical and prognosis data were recorded.
Results: Among 1688 adults hospitalized in the medicine department, 45
(2.7%) had symptomatic HF: 38 (84%) males, mean age 55.8 years (range 27-75).
Twenty five (56%) patients were initially hospitalized for acute pulmonary
oedema. New York Heart Association (NYHA) class was 2 (40%), 3 (44%) and
